(PharmaNewsWire.Com, February 15, 2017 ) Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer - the key indications covered in this report - accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.
A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.
Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies - such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.
- Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period? - The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market? - What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications? - How will the market shares and CAGRs of the top 20 companies compare within this therapy area? - What proportion of the key players' revenues will be attributable to urological cancers?
Reasons to buy
This report will allow you to - - Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis - Visualize the composition of the urological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players - Analyze the urological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications - Understand the growth in patient epidemiology and market revenues for the urological cancer market globally and across the key players and product types - Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various urological cancers - Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
